Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2003
12/24/2003CA2479309A1 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
12/24/2003CA2477878A1 Peptides selectively lethal to malignant and transformed mammalian cells
12/23/2003US6667404 Retroviral protease inhibiting compounds
12/23/2003US6667391 Can be used to produce monoclonal antibodies, as molecular weight markers, and as a food supplement.
12/23/2003US6667390 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of tumors, inflammation and shock
12/23/2003US6667388 Peptide inhibitor of MMP activity and angiogenesis
12/23/2003US6667345 Derivatives of C2-substituted indan-1-ol systems for the prophylaxis or treatment of obesity
12/23/2003US6667334 Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same
12/23/2003US6667331 Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
12/23/2003US6667330 Cytoprotective; neuroinflammation and neurodegenerative disorders; oxidative stress related conditions
12/23/2003US6667315 Pyridoxine phosphonate analogues such as, for example, ((2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl)alkylphosphonates, and (2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl)azaalkylphosphonates)
12/23/2003US6667305 Alzheimer's disease; beta-amyloid peptide is a small fragment of the amyloid precursor protein
12/23/2003US6667292 Metabolite is an s-nitroso-low molecular weight thiol compound, s-nitrosoglutathione; blood substitutes and organ perfusion solutions
12/23/2003US6667291 Endometrial Steroid Binding Protein II activity; endometrial and breast cancers
12/23/2003US6667174 Expression vectors containing hybrid ubiquitin promoters
12/23/2003US6667173 Antiscarring agents; wound healing agents
12/23/2003US6667162 Isolating the Fkhsf polypeptide from cultured recombinant host cells.
12/23/2003US6667157 Compositions and methods for the abrogation of cellular proliferation utilizing the human immunodeficiency virus VPR protein
12/23/2003US6667156 Treating nervous system tumors; obtain cells, incubate with modulator, evaluate tumor propagtion
12/23/2003US6667154 Contacting with an oligo- or polynucleotide that hybridizes to a specific sequence and comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value
12/23/2003US6667063 Nutritional or therapeutic supplement and method
12/23/2003US6667062 Soaking washed specimen in methanol, obtaining crude solvent extract from whole body tissue, decanting, filtering, evaporating filtrate at 40 degrees C. to concentrate, fractionating using solvents of increasing polarity
12/23/2003US6667052 Drug delivery; diabete therapy; penetration enhancer mixture of protein and oxidizer
12/23/2003US6667041 Use of neurotoxin therapy for treatment of urologic and related disorders
12/23/2003US6667039 Delivering therapeutic agent to CD30+ malignant cells by contacting with conjugate comprising one or more agents attached to soluble CD30 ligand polypeptide having specified amino acid sequence
12/23/2003US6667037 Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
12/23/2003US6667036 Administering antibody to a protein component or to a carbohydrate-protein component of P-selectin glycoprotein ligand for therapy of rheumatoid arthritis
12/23/2003US6667033 Administering daily effective dose of interferon-beta in two portions for four weeks
12/23/2003CA2149207C Compounds that inhibit t cell proliferation and methods using the same
12/21/2003CA2389462A1 Methods and compositions for preventing diabetes
12/19/2003WO2002101076A2 Methods for targeted expression of therapeutic nucleic acid
12/19/2003CA2460095A1 Methods for targeted expression of therapeutic nucleic acid
12/18/2003WO2003104818A1 Method for identifying agonists or antagonists for the g-protein coupled mas-like 1 receptor
12/18/2003WO2003104807A1 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action
12/18/2003WO2003104495A1 METHODS FOR BLOCKING ADIPOCYTE DIFFERENTIATION AND TRIGLYCERIDE ACCUMULATION WITH INTERLEUKIN 12 p35 INHIBITORS
12/18/2003WO2003104494A1 Methods for blocking adipocyte differentiation and triglyceride accumulation with g-alpha-i3 inhibitors
12/18/2003WO2003104485A2 Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
12/18/2003WO2003104477A2 METHODS FOR BLOCKING ADIPOCYTE DIFFERENTIATION AND TRIGLYCERIDE ACCUMULATION WITH TRANSCRIPTION FACTOR Dp-1 INHIBITORS
12/18/2003WO2003104468A1 A semliki forest virus based expression vector for the central nervous system
12/18/2003WO2003104466A1 Treatment of vascular dysfunction and alzheimer's disease
12/18/2003WO2003104458A1 Antisense modulation of il-1 receptor-associated kinase-1 expression
12/18/2003WO2003104454A1 Novel oxidase
12/18/2003WO2003104453A1 Method of constructing antibody
12/18/2003WO2003104437A2 Anti-addl antibodies and uses thereof
12/18/2003WO2003104429A2 Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
12/18/2003WO2003104428A2 Gene differentially expressed in breast and bladder cancer and encoded polypeptides
12/18/2003WO2003104426A2 Isolated nucleic acid molecule encoding a novel centromere-associated motor protein, and uses thereof
12/18/2003WO2003104422A2 Mahoganoid polypeptides, and related compositions and methods
12/18/2003WO2003104415A2 Method to screen ligands using eukaryotic cell display
12/18/2003WO2003104407A2 T cell receptor cdr3 sequences and methods for detection
12/18/2003WO2003104402A2 Non-polymeric hematopoietic cell clots for delivery of active agents
12/18/2003WO2003104401A2 Cancer-linked gene as target for chemotherapy
12/18/2003WO2003104397A2 Antisense modulation of g protein-coupled receptor kinase 6 expression
12/18/2003WO2003104395A2 Receptors and membrane-associated proteins
12/18/2003WO2003104381A2 Methods
12/18/2003WO2003104303A1 Polyaminoacids functionalized by alpha tocopherol and uses thereof, particular for therapeutic applications
12/18/2003WO2003104282A2 Immunoadhesin comprising a glycoprotein vi domain
12/18/2003WO2003104278A1 Tnf-like protein
12/18/2003WO2003104277A2 Stat6 activation gene
12/18/2003WO2003104274A1 Scorpion peptide as hypotensive agent
12/18/2003WO2003104273A2 Therapeutic epitopes and uses thereof
12/18/2003WO2003104272A1 Immunogenic compositions
12/18/2003WO2003104270A2 Dudulin 2 genes, expression products, non-human animal model: uses in human hematological disease
12/18/2003WO2003104269A1 Synthesis of the peptide cgggqrlgdqwavghlmnh2, labelling method
12/18/2003WO2003104268A1 Par-2-activating peptide derivative and pharmaceutical composition using the same
12/18/2003WO2003104267A1 Kit formulation of a novel peptide c-aca-qalgnqwavghlmnh2
12/18/2003WO2003104266A2 PEPTIDES AND PEPTIDOMIMETICS USEFUL FOR INHIBITING THE ACTIVITY OF PROSTAGLANDIN F2alpha RECEPTOR
12/18/2003WO2003104265A1 Compound having glycine transporter inhibition activity
12/18/2003WO2003104263A2 Cytokines and cytokine receptors with reduced immunogenicity
12/18/2003WO2003104262A2 Gp41 peptides and methods based-thereon for inhibiting hiv fusion to target cells
12/18/2003WO2003104260A2 Pharmaceutical formulation
12/18/2003WO2003104256A2 THE CaR RECEPTOR AS A MEDIATOR OF MIGRATORY CELL CHEMOTAXIS AND/OR CHEMOKINESIS
12/18/2003WO2003104217A2 Prodrugs of excitatory amino acids
12/18/2003WO2003104196A1 Non-peptidic brs-3 agonists
12/18/2003WO2003104184A1 Methods for synthesis of acyloxyalkyl derivatives of gaba analogs
12/18/2003WO2003103771A1 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor
12/18/2003WO2003103770A2 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
12/18/2003WO2003103743A2 Medical device for intra-lumenal delivery of pharmaceutical agents
12/18/2003WO2003103725A1 Compositions and methods for the diagnosis and treatment of tumor
12/18/2003WO2003103721A1 Gene therapeutic for cerebrovascular disorders
12/18/2003WO2003103720A2 Compositions and methods for the use of bcl-2 transfected neurons
12/18/2003WO2003103718A2 Intracellular delivery of biological effectors
12/18/2003WO2003103715A1 Modified byrodin 1 with reduced immunogenicity
12/18/2003WO2003103710A1 Combined effects of therapeutic or preventive agent composition for bone breakage
12/18/2003WO2003103709A2 Modulation of bone development
12/18/2003WO2003103705A1 Metalloproteinase inhibitors
12/18/2003WO2003103704A2 Proteins involved in the regulation of energy homeostasis
12/18/2003WO2003103703A1 Remedy for bone mtabolic diseases
12/18/2003WO2003103702A1 Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
12/18/2003WO2003103701A1 Compositions and methods for treating diabetes
12/18/2003WO2003103700A1 Method and composition for inhibing or slowing blood coagulation
12/18/2003WO2003103699A1 Use of ramoplanin to treat diseases associated with the use of antibiotics
12/18/2003WO2003103698A1 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
12/18/2003WO2003103697A2 Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
12/18/2003WO2003103677A1 Derivatives of azepine and thiazeran as interleukin converting enzyme inhibitors
12/18/2003WO2003103662A2 Inhibitors of glycoprotein vi
12/18/2003WO2003103613A2 Induction of insulin expression
12/18/2003WO2003103611A2 Methods and compositions for the repair and/or regeneration of damaged myocardium
12/18/2003WO2003103608A2 Neuroprotective synergy of erythropoietin and insulin-like growth factor
12/18/2003WO2003103597A2 Methods of diagnosing & treating diabetes and insulin resistance
1 ... 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 ... 3163